Clinical Trials Logo

Uterine Corpus Carcinosarcoma clinical trials

View clinical trials related to Uterine Corpus Carcinosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02874430 Active, not recruiting - Breast Carcinoma Clinical Trials

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Start date: June 8, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast or uterine cancer.

NCT ID: NCT02020707 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Start date: February 24, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.

NCT ID: NCT01935934 Active, not recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Start date: April 29, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.